Reflecting on Research in Genitourinary Cancers

NORTHAMPTON, MA / ACCESSWIRE / February 6, 2023 / Originally published on Bristol Myers Squibb News & Perspectives

Dana Walker, MD, MSCE, our vice president and Genitourinary (GU) Cancers Development Lead, sheds light on the importance of ongoing GU cancer research, the unmet needs for patients with GU tumors and where we go from here to offer hope to even more people impacted by cancer.

Dr. Walker: Hi, my name is Dana Walker. I'm the development program lead for genitourinary cancers here at Bristol Myers Squibb. I'm proud to lead a team of people continuing to develop treatments that help improve and extend the lives of patients dealing with genitourinary cancers. While many treatments have been developed over the last several years and we've had tremendous progress in this field, there's still a lot of work to be done and I'm excited for our team to be at the forefront of that progress.

Q: What does the treatment landscape currently look like for patients with GU cancers, and how does it differ from other areas?

Dr. Walker: GU cancer research has progressed significantly over the last several years in both the metastatic setting and in earlier stages of disease. Previously, the standard of care for many GU cancer types - including kidney cancer, bladder cancer and prostate cancer - was chemotherapy. However, over the last several years, we've seen many new modalities and mechanisms come into play - including immunotherapy, targeted agents, antibody drug conjugates and radioligand therapy in the metastatic setting, as well as some new data on immunotherapies in earlier lines of treatment for both kidney and bladder cancer. This is a really exciting time. Since GU cancers extend over multiple different tumor types, I think we have an opportunity here to explore a wide variety of mechanisms, both alone and in combination.

Q: In your opinion, what are the most exciting advancements or areas of research in this field?

Dr. Walker: Many new mechanisms have been established as standards of care across kidney, bladder and prostate cancers in recent years. Not only is BMS at the forefront with various treatments in these areas, but we've also had a great opportunity to collaborate across the global cancer community, including with industry partners and academic research institutions. In my opinion, a lot of the excitement lies in this ability to pursue novel combinations across mechanisms and expand the research to explore novel options.

So handeln Sie das Kursziel

Der Analyst erwartet ein Kursziel von 43,79$, was einem Rückgang von -2,57% zum aktuellen Kurs entspricht. Mit diesen Produkten können Sie die Kurserwartungen des Analysten übertreffen.

 

Vontobel

 

Alle Partner

Übernehmen

Für Ihre Einstellungen haben wir keine weiteren passenden Produkte gefunden.
Bitte verändern Sie Kursziel, Zeitraum oder Emittent.Alternativ können Sie auch unsere Derivate-Suchen verwenden
Knock-Out-Suche | Optionsschein-Suche | Zertifikate-Suche

WerbungDisclaimer